Last reviewed · How we verify
transcriptomic analysis
At a glance
| Generic name | transcriptomic analysis |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT) (PHASE2)
- Characterization and Support of Neurodevelopmental Disorders Associated With Congenital Cardiac malfoRmations - Neonatal
- Clinical and Mechanistic Study of Patients (With COVID-19 or Not) With a Recent Acrosyndrome (NA)
- ARTEMIS - The ARTEMIS Cohort
- Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis (PHASE4)
- Assesment of Multiomics Profiles in Health and Disease.
- Microfluidic Assessment of Clinical Outcomes in Preterm Newborns
- Circadian Rhythmicity During Coma Awakening (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- transcriptomic analysis CI brief — competitive landscape report
- transcriptomic analysis updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI